Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. [electronic resource]
Producer: 20200722Description: 685-696 p. digitalISSN:- 1365-2893
- 2-Naphthylamine
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anilides -- therapeutic use
- Antiviral Agents -- therapeutic use
- Carbamates -- therapeutic use
- Cyclopropanes
- Drug Interactions
- Drug Therapy, Combination
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C, Chronic -- drug therapy
- Humans
- Internationality
- Lactams, Macrocyclic
- Macrocyclic Compounds -- therapeutic use
- Male
- Middle Aged
- Proline -- analogs & derivatives
- Prospective Studies
- Ribavirin -- therapeutic use
- Ritonavir -- therapeutic use
- Sulfonamides -- therapeutic use
- Sustained Virologic Response
- Uracil -- analogs & derivatives
- Valine
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.